Whalesbook
Regulatory Milestone Validates CDMO Platform
The Health Canada approval for a generic semaglutide injection is a significant validation for OneSource Specialty Pharma's contract development and manufacturing organization (CDMO) platform. This milestone highlights the company's expertise in complex peptide synthesis and manufacturing for regulated markets, positioning its partners as early entrants in a critical global market.
Canada Opens Door for Generic Semaglutide
Health Canada's approval of a second generic semaglutide injection, backed by OneSource's manufacturing, strongly endorses its complex peptide therapeutic capabilities. Canada, the world's second-largest semaglutide market, offers a prime opportunity. Brand-name drugs like Novo Nordisk's Ozempic generate billions in revenue (approximately DKK 120,342 million for Ozempic in 2024 alone). With semaglutide's core patent expired in Canada, generic versions are set to disrupt the market, promising significant cost savings. Health Canada indicates generics can be 45% to 90% cheaper, with prices potentially halving as more generics become available.
Growth in Peptide CDMO Market
OneSource is active in the growing global peptide CDMO market, forecast to expand from USD 2.8 billion in 2025 to USD 5.1 billion by 2035. The broader peptide therapeutics CDMO market is projected to reach USD 8.14 billion by 2033, driven by increased biologic R&D, outsourcing trends, and synthesis advancements. OneSource's integrated model, featuring its US-FDA approved facility in Bengaluru, is designed to capture market share, especially in API development and manufacturing. This Canadian approval, following a US tentative approval, underscores the value of its international manufacturing network.
Analyst View and Company Valuation
Analyst firm DAM Capital initiated coverage with a 'Buy' rating on June 30, 2025, signaling positive sentiment for OneSource's growth. The company holds a market capitalization around ₹20,000 Cr. It also received an 'Environment, Social and Governance' (ESG) rating of '73' (Leader category) for FY25, noting its commitment to responsible business practices.
Financial Concerns and Market Risks
However, financial and operational concerns exist. OneSource Specialty Pharma shows a high P/E ratio, ranging from 114.15 to over 1,000, suggesting potential overvaluation. Profit and revenue growth have been reported at 0% over the past three years. The company also has a negative Return on Equity (-38.91%) and Return on Capital Employed (-13.73%) during the same period. Challenges include a low interest coverage ratio of 0.87 and negative cash flow from operations. Promoter pledging stands at a high 38.38%. The CDMO sector faces intensifying competition. Reliance on partners for product development introduces risks, as does the potential for price erosion from generic drug competition, impacting long-term revenue.
Future Prospects
The Health Canada approval is a key step for OneSource Specialty Pharma, confirming its complex peptide manufacturing expertise and capability in global regulatory filings. The company is poised to secure more contracts for high-value peptide generics, tapping into demand for biosimilars and complex drug combinations. Its US-FDA approved facilities offer a strong base for entering other regulated markets, aiming to offset price pressures through scale and production efficiency.